Navigation Links
Candidate vaccine to reduce hepatitis C viral load.

Hepatitis C virus is the leading cause of death and liver transplant in the western world. This disease is also very common that it is incidence is five times more when compared to HIV/ AIDS. // Hence researchers at the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine candidate to treat hepatitis C infection.

This vaccine technique is very effective in the treatment of Hepatitis C (HCV) infection. It reduced the load of the carrier virus in the body of the mice tremendously in the order of 100000 times when compared to the control. The Canadian Institutes of Health Research (CIHR) and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) funded the research.

The researchers mainly made use of the dendritic cells to fight against the Hepatitis C virus. Dendritic cells play an important role in activation of the immune system. The vaccine significantly reduced the amount of viral protein in the body. This help us to later develop treatments which will pave way to help the patients suffering from liver disease caused by the virus.

People (20%) who have the disease remove the virus without any major problem. When the disease becomes chronic then the immune system finds it difficult to remove the viral load from the body. But studies reveal that in patients suffering from chronic hepatitis there is alteration in the function of the dendritic cells.

Hence these vaccines were created which could signal the dendritic cell and help in the proper activation of the immune system. Then the patient is in a position to control from the body.

The designing of a vaccine is very time consuming and troublesome because the virus always keeps mutating. A patient suffering from the disease may harbor with many different types of strains. Hence the VIDO came up with a vaccine that has a broad range of action and is effective against all strains.


'"/>




Page: 1

Related medicine news :

1. New Test Identifies Candidates For Cardiac Defibrillator
2. HIV-Positive Woman To Be Congress Candidate In Assam
3. Reservation For SC/ST Candidates Under 50% All India Quota
4. New hope for cancer victims – will vaccine cure the deadly bug
5. New vaccine helps allergy and asthma patients
6. Man against HIV – new vaccine ready for human trials
7. New vaccine helps allergy and asthma patients
8. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
9. HIV did not arise from polio vaccine
10. Double impact vaccine
11. High Demand for a child vaccine
Post Your Comments:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10